ToleroTech has developed several product pipelines. ToleroTech’s product strategy is two-fold. In the short term, next two - three years, Tolerotech will develop and commercialize siRNA Organ Solutions. The next step will be developing siRNA drugs and vaccines to treat such as cancer, autoimmune diseases, and allergic diseases.
